- Trials with a EudraCT protocol (1,163)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,163 result(s) found for: Chronic Pain.
Displaying page 56 of 59.
| EudraCT Number: 2012-003937-41 | Sponsor Protocol Number: V102_03E1 | Start Date*: 2014-01-17 | |||||||||||
| Sponsor Name:GSK Vaccines S.r.l | |||||||||||||
| Full Title: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Follow... | |||||||||||||
| Medical condition: This study will evaluate the safety and immunogenicity of a booster dose of MenABCWY vaccine; either MenABCWY+OMV or MenABCWY+1/4OMV, administered to adolescent and young adults who previously rece... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000196-24 | Sponsor Protocol Number: 402-C-1504 | Start Date*: 2016-07-04 |
| Sponsor Name:Reata Pharmaceuticals, Inc. | ||
| Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION | ||
| Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-003577-27 | Sponsor Protocol Number: A6631007 | Start Date*: 2006-12-01 | |||||||||||
| Sponsor Name:Pfizer Luxembourg SARL Branch Office Estonia | |||||||||||||
| Full Title: A 12-WEEK, PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF PH-797804, ADMINISTERED ORALLY ONCE DAILY IN SUBJECTS WITH ACTIVE... | |||||||||||||
| Medical condition: Treatment of rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) CZ (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-008337-11 | Sponsor Protocol Number: A3921046 | Start Date*: 2009-05-27 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND DMARDS | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) ES (Completed) DE (Completed) GB (Completed) FI (Completed) PL (Completed) DK (Completed) SK (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020745-27 | Sponsor Protocol Number: D4300C00003 | Start Date*: 2010-11-23 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Respon... | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001313-93 | Sponsor Protocol Number: MN39159 | Start Date*: 2018-05-03 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
| Full Title: AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | ||||||||||||||||||
| Medical condition: Progressive multiple sclerosis (PMS) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IE (Completed) DK (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Completed) IT (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-020992-21 | Sponsor Protocol Number: AB06012 | Start Date*: 2014-03-25 | |||||||||||
| Sponsor Name:AB Science | |||||||||||||
| Full Title: A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg... | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000965-21 | Sponsor Protocol Number: OP-106 | Start Date*: 2016-10-27 | |||||||||||
| Sponsor Name:Oncopeptides AB | |||||||||||||
| Full Title: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. | |||||||||||||
| Medical condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002942-19 | Sponsor Protocol Number: NT-2020 | Start Date*: 2021-03-16 |
| Sponsor Name:Region Örebro län | ||
| Full Title: NORDTREAT The Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile | ||
| Medical condition: Crohn's disease and Ulcerative colitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Completed) DK (Completed) IS (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-003341-25 | Sponsor Protocol Number: IPP-201101/005 | Start Date*: 2016-05-02 | |||||||||||
| Sponsor Name:ImmuPharma SA | |||||||||||||
| Full Title: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lup... | |||||||||||||
| Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) DE (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-001834-25 | Sponsor Protocol Number: MasterDapt | Start Date*: 2017-11-07 | |||||||||||
| Sponsor Name:ECRI-9 | |||||||||||||
| Full Title: MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen – MASTER DAPT | |||||||||||||
| Medical condition: High bleeding risk population represents a significant proportion of coronary artery disease (CAD) patients undergoing coronary stent implantation. Decisions regarding the duration of dual antiplat... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004384-31 | Sponsor Protocol Number: SAG/0211PFC-11S1 | Start Date*: 2015-06-10 | |||||||||||
| Sponsor Name:Sucampo AG | |||||||||||||
| Full Title: A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥6 to <18 years with Functional Constipation | |||||||||||||
| Medical condition: functional constipation in paediatric patients | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Ongoing) NL (Completed) FR (Ongoing) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-020743-12 | Sponsor Protocol Number: D4300C00001 | Start Date*: 2010-10-26 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Res... | |||||||||||||
| Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Completed) DE (Completed) SK (Completed) HU (Completed) EE (Completed) PL (Completed) FR (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004194-27 | Sponsor Protocol Number: 112957 | Start Date*: 2015-06-24 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and si... | ||
| Medical condition: Active immunization against Haemophilus influenzae type b starting from 6 weeks of age as a 3-dose primary series with a single booster dose given at 15 to 18 months | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2005-003694-25 | Sponsor Protocol Number: PA18604 | Start Date*: 2006-01-27 |
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||
| Full Title: Ensayo randomizado, doble ciego, con doble enmascaramiento, de grupos paralelos para evaluar la eficacia y seguridad de RO4402257 como monoterapia en comparación con la monoterapia de metotrexato ... | ||
| Medical condition: Artritis Reumatoide Rheumatoid Arthritis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) IT (Completed) CZ (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-000230-33 | Sponsor Protocol Number: HYDROXYSSc | Start Date*: 2022-01-26 | |||||||||||||||||||||||||||||||
| Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||||||||||||||||||||||
| Full Title: A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc | |||||||||||||||||||||||||||||||||
| Medical condition: Systemic Sclerosis (SSc) is a rare and orphan disease (DPCM 12 gennaio 2017-GU SG n°65-S.O. n°15 - 18/03/2017), characterized by immunological, vascular and fibrotic abnormalities. The estimated in... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-000344-21 | Sponsor Protocol Number: MP1032-CT05 | Start Date*: 2021-07-21 | ||||||||||||||||||||||||||
| Sponsor Name:MetrioPharm AG | ||||||||||||||||||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD... | ||||||||||||||||||||||||||||
| Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2011-004720-35 | Sponsor Protocol Number: NORD-STAR | Start Date*: 2012-05-28 | |||||||||||
| Sponsor Name:The Karolinska Institute, ClinTRID | |||||||||||||
| Full Title: A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two d... | |||||||||||||
| Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) IS (Trial now transitioned) DK (Trial now transitioned) FI (Completed) NO (Trial now transitioned) NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000485-35 | Sponsor Protocol Number: LRS114689 | Start Date*: 2011-07-27 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
| Full Title: Study LRS114689: A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. | |||||||||||||
| Medical condition: Intra-abdominal infections. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-014735-20 | Sponsor Protocol Number: MI-CP219 | Start Date*: 2009-12-29 | |||||||||||
| Sponsor Name:MedImmune Ltd | |||||||||||||
| Full Title: A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) LT (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.